LGM Pharma

The Evolution of the CDMO Industry

The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine. CHEManager asked executives and industry experts from a broad range of CDMOs to share their views on how their companies are dealing with this changing economic environment and the resulting opportunities and challenges.

Expert Statement: Prasad Raje, LGM Pharma

The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.

LGM Pharma Buys Nexgen Assets

US API specialist LGM Pharma has acquired the formulation development and drug product contract manufacturing business of specialty pharma company Nexgen Pharma for an undisclosed sum.

The Latest From SOCMA